NCT02776215View on ClinicalTrials.gov

Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 4, 2016

Primary Completion Date

December 20, 2017

Study Completion Date

December 20, 2017

Conditions
Circadian Rhythm Sleep DisordersNon-24 Hour Sleep-Wake DisorderAutism Spectrum DisorderSmith-Magenis Syndrome
Interventions
DRUG

tasimelteon

Melatonin receptor agonist

Trial Locations (1)

21225

Parexel Early Phase Clinical Unit, Baltimore

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY